Bo Gao1, Feng-Mei Yang2, Zong-Tao Yu1, Rui Li3, Fei Xie1, Jie Chen4, Hai-Jun Luo5, Ji-Cai Zhang1. 1. Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. 2. Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. 3. Department of Infection Control, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China. 4. Department of Cardiology, Jiangyan District Third People's Hospital Taizhou 225500, Jiangsu China. 5. Department of Laboratory Medicine, The Hospital of Traditional Chinese Medicine Shiyan 442000, Hubei, China.
Abstract
OBJECTIVE: By the detection of HBV infection, AFP and AST, the targets of biological behavior and the gene expression of multi-drug resistance gene 1 (MDR1) in hepatocellular carcinoma (HCC), we investigate characteristics of the expression of MDR1 in HCC and its relationship with HCC biological behavior. METHODS: Using real-time fluorescence quantitative PCR (FQ-PCR) to detect the expressions of MDR1 in 102 samples of HCC tissue and 20 samples of non-cancerous tissue, we analyze the relationship between expressions of MDR1 and biological characteristics of HCC. RESULTS: The expression of MDR1 in HCC is 0.55 ± 0.27, and in normal liver tissues is 0.23 ± 0.10, respectively. The expression in HCC is higher than it in normal liver tissue, the difference is statistically significant (P<0.05) and the difference between the expression and the HCC envelopes is statistically significant, and the expression increases along with the increase of Edmondson classification (P<0.05). HBV infection, AFP positive, the rise of AST, all these factors have positive correlations with the expression (r=0.463, 0.473, 0.299). In MDR1 expressions of HCC patients, the survival curve of the negative is higher than that of the positive, but the difference is not statistically significant. CONCLUSION: There are drug resistance phenomena in HCC, MDR1 expression may play an important role in primary HCC drug resistance. HBV infection can be detected as a reference indicator of HCC chemotherapy resistance, plasma levels of AFP, AST can be used as a reference index change dynamic monitoring of MDR1 expression.
OBJECTIVE: By the detection of HBV infection, AFP and AST, the targets of biological behavior and the gene expression of multi-drug resistance gene 1 (MDR1) in hepatocellular carcinoma (HCC), we investigate characteristics of the expression of MDR1 in HCC and its relationship with HCC biological behavior. METHODS: Using real-time fluorescence quantitative PCR (FQ-PCR) to detect the expressions of MDR1 in 102 samples of HCC tissue and 20 samples of non-cancerous tissue, we analyze the relationship between expressions of MDR1 and biological characteristics of HCC. RESULTS: The expression of MDR1 in HCC is 0.55 ± 0.27, and in normal liver tissues is 0.23 ± 0.10, respectively. The expression in HCC is higher than it in normal liver tissue, the difference is statistically significant (P<0.05) and the difference between the expression and the HCC envelopes is statistically significant, and the expression increases along with the increase of Edmondson classification (P<0.05). HBV infection, AFP positive, the rise of AST, all these factors have positive correlations with the expression (r=0.463, 0.473, 0.299). In MDR1 expressions of HCC patients, the survival curve of the negative is higher than that of the positive, but the difference is not statistically significant. CONCLUSION: There are drug resistance phenomena in HCC, MDR1 expression may play an important role in primary HCC drug resistance. HBV infection can be detected as a reference indicator of HCC chemotherapy resistance, plasma levels of AFP, AST can be used as a reference index change dynamic monitoring of MDR1 expression.
Authors: P Verrelle; F Meissonnier; Y Fonck; V Feillel; C Dionet; F Kwiatkowski; R Plagne; J Chassagne Journal: J Natl Cancer Inst Date: 1991-01-16 Impact factor: 13.506
Authors: Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll Journal: BMC Urol Date: 2009-06-24 Impact factor: 2.264
Authors: Pablo Carabias; María V Espelt; María L Bacigalupo; Paola Rojas; Luciana Sarrias; Ayelén Rubin; Nicolás A Saffioti; María T Elola; Juan P Rossi; Carlota Wolfenstein-Todel; Gabriel A Rabinovich; María F Troncoso Journal: Cell Death Dis Date: 2022-01-24 Impact factor: 9.685
Authors: Andrea Savarino; Marina Lusic; Iart Luca Shytaj; Mohamed Fares; Lara Gallucci; Bojana Lucic; Mahmoud M Tolba; Liv Zimmermann; Julia M Adler; Na Xing; Judith Bushe; Achim D Gruber; Ina Ambiel; Ahmed Taha Ayoub; Mirko Cortese; Christopher J Neufeldt; Bettina Stolp; Mohamed Hossam Sobhy; Moustafa Fathy; Min Zhao; Vibor Laketa; Ricardo Sobhie Diaz; Richard E Sutton; Petr Chlanda; Steeve Boulant; Ralf Bartenschlager; Megan L Stanifer; Oliver T Fackler; Jakob Trimpert Journal: mBio Date: 2022-03-01 Impact factor: 7.786
Authors: Jose J G Marin; Maria J Monte; Rocio I R Macias; Marta R Romero; Elisa Herraez; Maitane Asensio; Sara Ortiz-Rivero; Candela Cives-Losada; Silvia Di Giacomo; Javier Gonzalez-Gallego; Jose L Mauriz; Thomas Efferth; Oscar Briz Journal: Cancers (Basel) Date: 2022-07-20 Impact factor: 6.575